SV health investors | All you need about it

Naarden, NL, 12 April 2022 – Prilenia Therapeutics B.V., a medical-level biotechnology business enterprise targeted at the pressing challenge to broaden novel therapeutics to gradual the development of neurodegenerative and neurodevelopmental disorders, these days introduced that it has raised an extra $10 million, bolstering the Series B financing spherical and bringing general capital raised to now to $a hundred and forty-four million. SV health investors

​The 2nd remaining consists of a new investor,

SV Health Investors, a main transatlantic mission capital and increase fairness organization with workplaces in Boston and London dedicated to investing in tomorrow`s healthcare breakthroughs. SV joins Prilenia`s preliminary Series B buyers Sands Capital, Forbion, Morningside, and Amplitude Ventures, in addition to Sectoral Asset Management, Talisman, and the ALS Investment Fund. Proceeds from the financing will permit Prilenia to preserve the sturdy momentum of its lead drug candidate, pridopidine, for sufferers with Huntington`s Disease (HD) and Amyotrophic Lateral Sclerosis (ALS) via 2024. Data readouts for each of Prilenia`s medical trials are anticipated withinside the subsequent 12 months.

​In conjunction with the financing, Houman Ashrafian, Managing Partner at SV Health Investors, co-lead of SV`s Biotech franchise, will be a part of the Company`s Board of Directors.

The SV Biotech price range spends money on groups constructed on novel science, in search of breakthroughs that cope with crucial unmet scientific wishes with the capability to extrude the exercise of medicine. Houman has tremendous enjoyment withinside the biotech enterprise and protracted records of constructing excessive value, a success new groups, and bringing transformational pills from discovery to market.

“Prilenia`s novel Sigma-1 Receptor agonist method represents a promising healing development for sufferers with HD and ALS – devastating neurodegenerative sicknesses with an unmet want for remedy,” stated Houman Ashrafian. “There is tremendous capability in the back of pridopidine, and SV is asking ahead to assist the Company along the sturdy management music document of Dr.

Michael Hayden and the Prilenia team.”

“Since Prilenia`s founding, our dedication to sufferers has been the using pressure in the back of all of our efforts, and those extra price range similarly assists our challenge of supplying wish to sufferers and families,” stated Dr. Michael R. Hayden, CEO, and Founder of Prilenia. “We are passionate in our notion that progressive drug improvement could have a transformative effect on sufferers, and we’re thrilled to welcome SV and to have Houman be a part of our board as we paintings with urgency to broaden probably life-converting therapeutics for neurodegenerative sicknesses.”

This 2nd remaining similarly strengthens Prilenia`s efforts and is sponsored through the latest milestones,

inclusive of the final touch of affected person enrollment withinside the Pridopidine Outcome On Function in Huntington`s Disease (PROOF-HD) Global Phase three Clinical Trial and the HEALEY ALS Platform Trial. In addition, Prilenia these days acquired Fast Track designation for pridopidine for the remedy of HD. This permits extra common communications Takedietplan with the FDA and might additionally qualify for increased approval and precedence evaluation of recent drug applications. Upcoming milestones for the Company consist of sharing information from the HEALEY ALS Platform Trial in past due 2022 and PROOF-HD top-line effects in early 2023.